Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nevirapine - Boehringer Ingelheim

Drug Profile

Nevirapine - Boehringer Ingelheim

Alternative Names: BI-RG-587; BIRG 0587; Extended release nevirapine; Nevirapine ER; Nevirapine XR; NSC 641530; Viramune; Viramune Extended Release; Viramune XR

Latest Information Update: 23 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class 3-ring heterocyclic compounds; Antiretrovirals; Azepines; Cyclopropanes; Pyridines; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections
  • Phase III HIV infections

Most Recent Events

  • 23 May 2012 Generic nevirapine equivalent available in the US for HIV-1 infections
  • 07 Feb 2012 Boehringer Ingelheim completes a phase III trial of extended-release nevirapine in HIV-1 infections (treatment-naive) in US, Argentina, Australia, Belgium, Botswana, Canada, France, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Romania, Russia, South Africa, Spain, Switzerland & UK (NCT00561925)
  • 21 Sep 2011 Registered for HIV-1 infections in European Union and in Liechtenstein, Iceland and Norway (PO once-daily, controlled release)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top